1227055-11-9

Basic information

• Product Name: 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone
• Synonyms: 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone
• CAS NO: 1227055-11-9
• Molecular Weight: 265.235
• Mol File: 1227055-11-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone(1227055-11-9)
• EPA Substance Registry System: 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone(1227055-11-9)

Safety Data

• Hazardous Substances Data: 1227055-11-9(Hazardous Substances Data)

Upstream product

• 49669-13-8 1-(6-bromopyridin-2-yl)-ethanone 
• 1423-26-3 (meta-(trifluoromethyl)phenyl)boronic acid 
• 401-78-5 3-bromo-1-trifluoromethylbenzene 
• 325142-82-3 4,4,5,5-tetramethyl-2-(3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane 

Downstream Products

• 1227055-12-0 1-(6-(3-(trifluoromethyl)phenyl)pyridin-2-yl)ethanone oxime 

Relevant articles and documents

Efficient yellow OLEDs based on bis-tridentate iridium(III) complexes with two C∧N∧N-coordinating ligands

Four bis-tridentate iridium(III) complexes with two different C∧N∧N-coordinating ligands have been synthesized and characterized. All complexes exhibited yellow/orange emission peaking at 580–604 nm with short lifetimes of 1.4–1.6 μs

PYRIDINE, BICYCLIC PYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS

The present invention provides novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders relating to aging or stress, diabetes, obesity, neurodegenerative disease, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorder that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. The compounds are of general formula (III) wherein R1, R2, R", X, Y, W, Z1 and Z2 are as defined in the specification.